Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study

Atsushi Itsukaichi,* Fukumi Yoshikawa,* Ayako Fuchigami, Yoko Iwata, Genki Sato, Masahiko Miyagi, Takahisa Hirose, Hiroshi Uchino Department of Diabetes, Metabolism and Endocrinology, Toho University Graduate School of Medicine, Tokyo, Japan*These authors contributed equally...

Full description

Saved in:
Bibliographic Details
Main Authors: Itsukaichi A, Yoshikawa F, Fuchigami A, Iwata Y, Sato G, Miyagi M, Hirose T, Uchino H
Format: Article
Language:English
Published: Dove Medical Press 2025-01-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
imeglimin
dpp-4 inhibitor
time in range
glycemic variability
continuous glucose monitoring
meal tolerance test
Online Access:https://www.dovepress.com/effect-of-imeglimin-a-novel-anti-diabetic-agent-on-insulin-secretion-a-peer-reviewed-fulltext-article-DMSO
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/effect-of-imeglimin-a-novel-anti-diabetic-agent-on-insulin-secretion-a-peer-reviewed-fulltext-article-DMSO

Similar Items